PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-5.73%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-4.82%
Negative net income growth while Biotechnology median is 1.06%. Seth Klarman would investigate factors dragging net income down.
-5.05%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-5.05%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3274.19%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-3274.19%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.86%
OCF/share CAGR of 47.86% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
47.86%
OCF/share CAGR of 47.86% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
47.86%
3Y OCF/share growth of 47.86% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
60.77%
Net income/share CAGR of 60.77% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
60.77%
Net income/share CAGR of 60.77% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
60.77%
3Y net income/share CAGR > 1.5x Biotechnology median of 6.40%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.11%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-4.64%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
8.65%
Debt growth of 8.65% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
6.08%
SG&A growth of 6.08% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.